Record revenue, but margin recovery delayed by tariff tailwinds & execution risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 broadly in line with FY27 guidance ₹5,500 Cr / 13% margins; margin recovery thesis underway but slower than prior aspiration (13% vs 15–16%)
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong top-line momentum (revenue +25.9% YoY, new business ₹387 Cr tracking to ₹1,500 Cr guidance) offset by margin disappointment (13.1% vs 15–16% target still ~200 bps away) and near-term execution risks (Bhilad 20-day closure, container constraints, product mix headwind). Guidance maintained at ₹5,500 Cr FY27, ~13% EBITDA; FTA tailwinds credible but 12–18 month ramp means near-term volatility likely.
₹1207 Cr
Revenue · +25.9% YoY₹63.2 Cr
Reported PAT · +67.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Highest ever quarterly revenue delivered
MET₹1,207 Cr delivered; total income ₹1,224 Cr (+27% YoY, but revenue only +25.9%)
EBITDA margin on recovery trajectory, ~13% guided for FY27
METQ1 EBITDA margin 13.1%, up 241 bps QoQ, 74 bps YoY from prior-year tariff trough
New business nearly tripled over past one year
METQ1 new business ₹387 Cr; guidance ₹1,500 Cr FY27 = on track; annualized Q1 ~₹1,548 Cr ≈ 60% of $275M USD target
US operations 60–65% utilization despite new NC greenfield
METQ1 achieved 60–65% utilization post-January 2026 NC facility ramp; management guides full-year stable at this level
Product mix drove realization headwind; Q1 bed-linen realization +1.5% YoY despite 9–10% rupee depreciation
METAdmitted product mix impact Q1; price hikes negotiated with customers, impacts expected Q2 onwards
Earnings quality
What changed since the last call
Margin recovery narrative unchanged; execution slower than hoped
NeutralPrior guidance: 15–16% EBITDA + tariff costs 150–200 bps to be eliminated Q1 FY27. Delivered: 13.1% EBITDA margin. Gap remains 190–290 bps; management attributes to gestation (new facility OpEx, ramp costs). No formal cut to target, but timeline clearly extended.
New business trajectory confirmed; on track to ₹1,500 Cr FY27
UpgradeQ1 ₹387 Cr vs ₹1,500 Cr full-year guidance = 26% of target achieved in Q1; annualized run rate ₹1,548 Cr already ~60% of $275M USD ambition (2028). No raise to full-year target but execution pace impressive.
Tariff refund expectation reset to minimal
DowngradePrior calls implied potential tariff refund upside. Q1 call: 80% of exports on FOB basis (importer bears tariff); no material benefit expected to company. Removes bull case element.
Container availability improved but ongoing
NeutralQ1 volume -3% YoY due to West Asia conflict constraints. Management expects momentum to strengthen; issue continues but visibility improving. No guidance change.
The Q&A
Analysts pressed on margin recovery timeline (why not 15–16% yet?), product mix headwind (realization only +1.5% YoY despite rupee), and Bhilad impact. Management cautious but confident: deflected precise margin guidance with 'not a magician' tone, reiterated price conversations concluded (impacts Q2+), and assured facility recovery is insured. Overall tone: honest on challenges, holding guidance, not capitulating.
Bhilad disruption impact — Abhishek
PartialFully insured facility. Confident to serve all customers; will make up lost ground over next couple quarters. Endeavor to offset production loss in other plants.
Tariff refund expectations — Navin Baid
AnsweredNo tariff refund in Q1 at this point of time.
Tariff refund forward outlook — Bhavin Chheda
AnsweredDo not expect material financial benefit. Nearly 80% exports FOB (importer bears tariff). Process evolving, discussions ongoing; premature to quantify. Clarity expected by end of year.
Core bed-linen realizations — Bhavin Chheda
AnsweredProduct mix impact in Q1. Price conversations concluded with all customers; impacts from Q2 onwards. Realizations will be fine on yearly basis.
Non-US growth opportunity — Bhavin Chheda
AnsweredUK business 8–10% of total. Active office with increased interactions (4× to 8× annually). FTA impact takes 12–18 months to pan out. Visibility positive going forward.
Standalone margin trajectory — Kaustubh Pawaskar
PartialCannot guide at precise level. Endeavor is 13% blended margin consolidated basis. Some quarter-to-quarter variation normal; full-year effort is to maintain.
New business utilization ramp — Shradha Agrawal
PartialEffort is 60–65% utilization full-year. New facility came mid-Jan; achieved those levels Q1, stable for rest of year. Ups and downs expected; satisfied at current level.
Margin ceiling / long-term potential — Pranav Malhotra
AnsweredNo ceiling in mind. Target to stabilize at 15–16% long-term; will recalibrate as business/market evolves. One step at a time (coming through tariff situation).
US volume upside beyond guidance — Pranav Malhotra
AnsweredComfortable with 105–110M meters, keeping customer offtake on positive side.
Guidance
FY27 ₹5,500 Cr (₹4,000 Cr core + ₹1,500 Cr new business)
HighQ1 total income ₹1,224 Cr; guidance reaffirmed 'in line with stated guidance.' Embedded in both core (105–110M meter volume) and new business (₹1,500 Cr target, Q1 on pace)
Non-US core revenue growth 20%+ FY27
MediumFTA tailwinds (UK live, EU pending) but 12–18 month ramp expected. Q1 non-US ~30% of core; growth dependent on customer onboarding post-FTA
CY2028 ₹8,000 Cr revenue + USD 275M new business ambition
MediumLong-term structural target; Q1 new business annualized at ~60% of USD 275M run rate. Requires continued margin recovery, tariff stability, and branded business scaling
FY27 ~13% EBITDA margin (blended consolidated)
HighQ1 achieved 13.1%. Management endeavor is to maintain 13% full-year 'some quarter-to-quarter variation normal.' Below prior 15–16% aspiration but reaffirmed
Long-term 15–16% EBITDA margin (company-wide stabilization target)
MediumPrior guidance implied tariff costs 150–200 bps eliminated by Q1 FY27. Delivered margin gap 190–290 bps from target; timeline extended. Mechanism: new facility ramp-up, product mix recovery, operational leverage
Bed-linen business: 15% long-term margin target
MediumQ1 stand-alone slightly >15% (core business); Q1 blended 13.1%. Realization pressure (product mix headwind) offset by Q2+ price hikes
New business (utility bedding + brands) long-term: 15% + (brands 100–200 bps premium)
LowCurrently ramping; gestation period ongoing. Brands targeting 17–18% margin at USD 100M scale (still investment phase)
Greenfield NC facility (January 2026) now operational; no major new capex disclosed
HighFacility ramping to 60–65% utilization Q1. Management: 'increasing scale of operations every quarter.' Further investment 'balancing' (70–75% in place, evolving business)
Risks the call surfaced
Operational disruption
MediumFacility down 15–20 days due to heavy rainfall/flooding (July 23–Aug 12). Partially resumed operations Aug 12 with phased normalization. Impact on Q2 volumes TBD; insured for property, inventory, loss of profit.
Logistics / supply chain
MediumWest Asia conflict disruptions ongoing; Q1 volume -3% YoY due to dispatch delays. Management expects momentum to strengthen but acknowledges issue continues. Q1 volume not to be treated as full-year benchmark (Q1 typically softer).
Pricing power / realization
MediumBed-linen realization ₹357/meter only +1.5% YoY despite 9–10% rupee depreciation and tariff coming down from 50% to 10%. Product mix shift into lower-realization products; price increase negotiations are ongoing (impacts Q2+). Risk: customer pushback on price hikes or delayed pass-through.
Margin recovery / execution
HighPrior FY26 calls promised 15–16% EBITDA margin + tariff cost elimination by Q1 FY27. Delivered Q1: 13.1% EBITDA margin = 190–290 bps below target. Root cause: new facility gestation period (OpEx, ramp costs) + product mix headwind. Risk: if margin recovery extends beyond FY27, equity upside capped.
Tariff / trade policy
LowPrior bull case expected tariff refund benefit. Q1 clarification: 80% of exports on FOB basis (importer bears tariff), minimal company benefit expected. Additionally, neighboring countries (India 10%, Vietnam/Bangladesh 10–12.5%) enjoy tariff parity; limited pricing power upside from tariff normalization.
Management
Score 7/10. Direct on near-term challenges (Bhilad, container, product mix); cautious on precise margin timing ('not a magician'). Transparent on tariff refund limitations (80% FOB). Weak on Q&A follow-up depth (e.g., Kalash on new business quarterly variability answered with 'very new for us'). Track record mixed: new business ₹387 Cr Q1 (on pace ₹1,500 Cr FY27, 60% of $275M USD target) strong. Core volume recovery +12% QoQ validates tariff normalization. EBITDA margin gap (13.1% vs 15–16% prior promise) = 190–290 bps miss suggests slower execution or revised assumptions.
1 · Q2 FY27
Price increases negotiated with core customers to flow through; seasonal demand uptick (US festive)
2 · H2 FY27
Bhilad operations normalization; volume recovery post-closure and container constraint easing
3 · CY2026–2027
EU FTA ratification + UK FTA expansion expected to drive non-US revenue growth 20%+ (12–18 month ramp)
Guidance maintained at ₹5,500 Cr FY27, ~13% EBITDA; FTA tailwinds credible but 12–18 month ramp means near-term volatility likely.
Record volume masks a margin recovery now running 12–18 months behind
₹1,207 Cr revenue is the highest ever, and net profit surged 67%. But management reaffirmed FY27 guidance at ₹5,500 Cr rather than raise it. The margin gap—13.1% delivered vs. 15–16% long-term target—is the real story.
Indo Count delivered its highest-ever quarterly revenue at ₹1,207 Cr (+25.9% YoY), with net profit surging 67.3% to ₹63.2 Cr. On the surface, it reads as a blowout. But the company reaffirmed FY27 revenue guidance at ₹5,500 Cr without raising it—a signal that near-term momentum masks underlying execution delays. The real story sits in the margin: 13.1% EBITDA in Q1, up 74 bps YoY but still 190–290 bps below the 15–16% long-term target that management promised two quarters ago.
₹1,207 Cr
+25.9% YoY; highest ever
13.1%
Target now 13% FY27, vs. 15–16% prior aspiration
₹387 Cr
+97% YoY; 26% of FY27 ₹1,500 Cr guidance
₹357/meter
+1.5% YoY (vs. +10% rupee depreciation)
The margin promise, and where it went
In the FY26 calls, management laid out a clear roadmap: tariff-related cost drag of 150–200 bps would be eliminated by Q1 FY27, unlocking a jump to 15–16% EBITDA margins. Instead, Q1 delivered 13.1%—a gap of 190–290 bps from that target. On the call, management attributed this to the gestation phase of new facilities (Ohio, Arizona, North Carolina capacity coming online) and product mix pressure in the core bed-linen business. Neither is wrong, but neither was unexpected either. The timeline slippage signals that the company is now several quarters behind on the margin recovery story.
The core business is masking its own headwinds
New business scaling (utility bedding and brands) is the bright spot: ₹387 Cr in Q1, annualized run rate of ~₹1,548 Cr is already 60% of the USD 275 million global target by 2028. But the core bed-linen franchise—the bread-and-butter that generates 70% of revenue—is running into pricing pushback. Bed-linen realization came in at ₹357/meter, up just 1.5% YoY, despite a 9–10% rupee depreciation and tariffs falling from 50% to 10%. That gap—between the headwind the rupee should have removed and what actually made it to pricing—is product mix drift: Indo Count is selling a higher proportion of lower-realization items. Management flagged this on the call and noted that price increases are negotiated and expected to flow through from Q2 onwards. But that's a forward-looking hedge, not a solved problem.
What management claimed vs. what holds up
Highest-ever quarterly revenue delivered
EBITDA margin on recovery trajectory; 13% guided for FY27
New business nearly tripled over the past year
US operations stable at 60–65% utilization despite NC greenfield
Bhilad facility disruption fully insured; confident to make up lost ground
Verdict summary: All supported by the numbers, but with important caveats. The margin target has shifted from 15–16% to 13% FY27; the timeline is extended, not accelerated. New business is tracking well, but at 60–65% utilization on the US greenfield (Jan 2026 ramp), there's execution risk if demand doesn't hold. Bhilad's closure (July 23–Aug 12, ~15–20 days) is insured for property and business interruption, but volume recovery will take several quarters to absorb.
What changed on this call
Three things shifted from the prior quarter's narrative:
Tariff refund upside removed. Prior bull case expected a US tariff refund benefit. Q1 clarification: nearly 80% of exports are on FOB basis (importer bears tariff), so the company expects no material financial benefit. This removes a tail case for upside.
Margin recovery timeline extended. Prior guidance: 15–16% EBITDA + 150–200 bps tariff cost elimination by Q1 FY27. Delivered: 13.1% and no cut to the long-term 15–16% target, but the path is now murkier. Management uses the word 'endeavor' repeatedly—honest, but vague.
New business trajectory confirmed on track. Q1 ₹387 Cr annualized is 60% of the $275M USD 2028 target already. This is the one genuine upgrade: execution on new capacity ramp (Ohio, Arizona, NC) is real and ahead of some expectations.
The bull case and the bear case
The bull: New business momentum is accelerating (₹387 Cr Q1, ₹1,500 Cr guided FY27 = 26% of target already captured). Revenue double from FY26 to FY28 is credible at current trajectory. FTA tailwinds (UK live, EU pending, US deal improving) will drive a structural shift—the company is positioned to gain share on tariff normalization. Long-term targets of ₹8,000 Cr CY2028 revenue + USD 275M new business are quantified and grounded in visible facility ramps. The stock is up 100.6% from its 52-week low; recovery narrative is intact.
The bear: Margin recovery is delayed 12–18 months from the plan. The gap between 13.1% delivered and 15–16% targeted is 190–290 bps—a structural headwind, not a temporary one. Product mix drag is not a one-quarter issue; it signals ongoing pricing pressure in the core business. Bhilad's 15–20 day closure will crimp Q2 volume recovery. Container availability constraints (West Asia conflict) are improving but not yet normalized; volume -3% YoY in Q1 is a drag. Management's tone on guidance ('not a magician') signals cautious near-term.
How the street is reading this
The market's first reaction was to sell: day 1 post-result, down 3.26% (delivery 48.5%, suggesting institutional buyers stepping in), day 3 still -3.44%. But by day 5, the stock recovered, closing up 9.76% from pre-result levels. Current price ₹435.1 sits above its 20-day, 50-day, and 200-day moving averages (₹412.95, ₹405.28, ₹310.99 respectively), confirming the recovery is not a one-day reversal—it's a reposturing. The stock is -6.19% from its all-time high of ₹463.8 but +100.6% off its 52-week low of ₹216.9, which is the arc of a turnaround narrative re-validating itself.
Ownership flows: FII holdings ticked up 29 bps QoQ to 10.14% (from 9.85%), and DII added 10 bps to 5.82%. Promoter remains stable at 58.74%. This is modest institutional accumulation, not a rush—consistent with the 'steady, not explosive' read on fundamentals. Bulk deals show a small trade at ₹444–₹445 (linked entity), not a signal of insider conviction or concern.
The street's takeaway: record revenue is priced in, but margin recovery is the debate. The day-5 recovery (and current positioning above key averages) suggests the market is giving the company credit for new business momentum while staying cautious on core margin recovery until Q2 delivery becomes clearer.
Risks, ranked by how much they should concern a holder
Margin recovery extending beyond FY27
High190–290 bps gap from 15–16% target signals gestation phase lasting longer than expected. If new facility ramp-up and product mix recovery take 18+ months, equity multiple re-rating is at risk.
Product mix headwind persists in core bed-linen
MediumRealization +1.5% YoY vs. 10% rupee tailwind = structural pricing pressure. Q2+ price hikes are promised but execution risk exists if customers resist or demand softens.
Bhilad disruption Q2 volume recovery
Medium15–20 day facility closure (July 23–Aug 12) is insured for property/business interruption, but production loss must be absorbed over next 2–3 quarters. Volume guidance 105–110M meters FY27 assumes normal operations by Q2+.
New facility utilization stalls below 70%
MediumOhio, Arizona, NC greenfields currently at 60–65% utilization Q1, guided to stay stable full-year. If demand doesn't accelerate, fixed cost drag persists and margin recovery is further delayed.
Container constraints extend beyond current expectations
MediumWest Asia conflict drove -3% YoY volume in Q1. While management expects normalization, geopolitical risk remains. A sustained closure of key shipping routes would hit FY27 guidance volume and realization.
What to watch next
1 · Q2 bed-linen realization and price flow-through
Management promised price increases would flow through from Q2 onwards. This is the test of whether the product mix headwind can be absorbed or if customer pushback stalls it. Watch for realization/meter data in next quarter.
2 · Bhilad operations normalization and volume recovery
The facility partially resumed Aug 12 with phased normalization expected. Q2 volume will signal whether the company can absorb the 15–20 day production loss or if it cascades into guidance miss.
3 · New facility utilization trajectory (Ohio, Arizona, NC)
Currently 60–65% stable Q1, but management's 'endeavor' to keep it there suggests upside is not yet visible. If utilization ticks to 70%+ or demand signals improve, margin recovery accelerates; if flat, gestation phase extends.
4 · FTA impact visibility on non-US revenue growth
UK FTA is live, EU pending. Management guides 20%+ non-US core revenue growth FY27 with 12–18 month ramp. Clarity on customer onboarding and order pipeline in Q2 call will validate or temper the FTA tailwind assumption.
Indo Count is executing its new business roadmap and the tariff normalization is real. Revenue scale and FTA access are credible. But the margin recovery narrative that was supposed to drive equity returns has now been delayed 12–18 months, and the core bed-linen business is running into pricing pressure that rupee depreciation and tariff cuts have not solved. This is not a broken quarter or a broken company—it's a steady execution story where near-term volatility (Bhilad, mix pressure, container constraints) will test patience before the long-term targets come into view.
The number to track from here is EBITDA margin. Watch whether Q2 realization bounces on price increases (validating the management thesis) or holds flat (signaling persistent mix drag). If margin moves materially toward the 13% full-year guidance—and shows a credible path to 15%+ in FY28—the long-term growth story becomes investable. Until then, hold is warranted; the recovery is real but not yet proven at the bottom line.
Flooding Headwind in the Mix; Expansion Capex in Motion
Indo Count reports Q1 FY27 results on Aug 12. A temporary disruption at the flagship Bhilad facility in late July clouds near-term output, but the ₹60 Cr spinning-facility expansion anchors the longer-term growth story.
The Setup: Capex Cycle Meets Operational Disruption
Indo Count is a vertically integrated textiles player — spinning, weaving, processing, and specialized home textiles. FY26 closed stable with revenue of ₹4,211 Cr (vs ₹4,211 Cr in FY25) and PAT of ₹126.67 Cr. The board approved a ₹1.5 dividend per share on the back of that. Now, heading into Q1 FY27, the picture is complicated: capex acceleration is underway (₹60 Cr brownfield expansion at the Alte, Kolhapur spinning facility to add 24,000 spindles), but the Bhilad, Gujarat facility went offline from July 23 onwards due to heavy monsoon flooding. How much of Q1 did it lose? That's the day-one question on Aug 12.
~₹1,050–1,100 Cr
On a run-rate from FY26 (₹4,211 ÷ 4 = ~₹1,053 Cr/quarter). Bhilad disruption could shave ₹30–50 Cr depending on downtime depth.
EBITDA likely 10–12%
FY26 profile was healthy; Q1 disruption cost likely reflected as one-time capacity underutilization.
₹60 Cr spinning facility (Alte)
Revised timeline: ready by Q2 FY28 (pushed from Q1 FY28). Execution risk and funding source (debt/internal/mix) to clarify.
USD revenue trend positive
FY26 saw new-business revenue increase off USD denominated products. Trajectory into Q1 FY27 depends on order traction & export realization.
What Strong vs. Weak Looks Like
A strong Q1 print: Revenue in-line or better than run-rate (~₹1,050 Cr+); Bhilad disruption quantified as A weak print: Revenue misses run-rate (below ₹1,000 Cr); Bhilad disruption extends beyond July (recovery TBD); margin compression >150 bps from FY26; Alte capex financing unclear or timeline slips further; no clear path to offset production shortfall. Forward guidance withdraw or negative.
On Track? The Trajectory Question
Indo Count has signalled stable revenue and modest profitability for FY26. The company is not a growth star — rather, a stable-to-modest-growth play anchored in established home-textiles verticals. The capex expansion (₹60 Cr to add 24k spindles) is a multi-year volume bet, with expected completion in Q2 FY28. This year's guidance will hinge on: (a) confidence in Bhilad recovery, (b) Alte capex disbursement & progress, (c) new-business momentum (USD revenue, order book). If Bhilad disruption is temporary and contained, and Alte capex proceeds on track, the company remains on its stated trajectory (stable revenue + margin resilience). If disruption lingers or capex slips, FY27 growth will be subdued.
Since Last Quarter: Filings & Events
1 · Bhilad Facility Disruption (Jul 23–24, 2026)
Heavy monsoon rainfall halted operations at the Bhilad, Gujarat facility. No damage to equipment or personnel reported; safety ensured. Restart timeline TBD. Impact on Q2 FY27 output material; Q1 not affected (Bhilad disruption is post-Q1 close).
2 · Spinning Facility Expansion Approved (May 30, 2026)
Board approved ₹60 Cr brownfield capex to expand Alte, Kolhapur spinning facility from 70,000 to 94,000 spindles. Revised timeline: ready by Q2 FY28 (previously Q1 FY28). This is a core growth lever for medium-term capacity & volume.
3 · Management Change: Head of Accounts Resigned (Jun 24, 2026)
Mr. Bijay Agarwal, Head of Accounts & Finance (Senior Management), resigned effective Sept 22, 2026. Routine change; no controversy flagged in the disclosure.
4 · BRSR & Annual Report Filed (Aug 3, 2026)
Company filed its Business Responsibility & Sustainability Report for FY 2025–26 and released its Annual Report. 37th AGM scheduled for Aug 25, 2026. Book closure for dividend: Aug 17, 2026. Routine governance.
5 · Board Dividend Recommendation (May 30, 2026)
Board recommended final dividend of ₹1.5 per share (75% of face value ₹2) for FY26, subject to AGM approval. Reflects confidence in cash generation despite modest growth.
The Street View (limited coverage)
Price & Technical Context
ICIL closed at ₹425 on Aug 10, 2026 — bullish trend, above SMA20 (₹406.2), SMA50 (₹392.48), and SMA200 (₹305.56). Price is -8.32% off the 52-week ATH (₹463.55) and +95.76% off the 52-week low (₹217.1). RSI at 69.5 suggests neutral-to-overbought. FII holding 10.14%, DII 5.82%, promoter 58.74% (stable). Volume trend normal. The stock has recovered sharply from last year's lows, suggesting investors are re-rating the capex story and dividend stability.
What to Watch on Aug 12
1. Bhilad Impact Disclosure: Quantify the disruption (downtime, output loss, repair cost). Any restart date communicated? 2. Alte Capex Progress: Capex spending in Q1, financing plan, expected delivery milestone, revised capex budget (if any). Are we on track for Q2 FY28 commissioning? 3. Revenue & Margin Trajectory: Confirm Q1 FY27 revenue run-rate. Has margin held or compressed? What is management's full-year FY27 guidance? Is dividend at risk? 4. New-Business Traction: Order book trends, export realization, customer wins. Is USD revenue momentum sustained? 5. Debt & Balance Sheet: Capex will be debt-funded. What is the revised leverage profile (Debt/EBITDA)? Any covenant risks?
Indo Count enters Q1 FY27 as a stable, dividend-paying textiles manufacturer pivoting toward capex-led growth. The Bhilad flooding is a near-term cloud, but Q1 (Apr–Jun) was unaffected; the hit lands in Q2. The real story is Alte: a ₹60 Cr bet to add 24,000 spindles by Q2 FY28. Execution here — on time, on budget — will define the medium-term narrative. Investors are paying for stability + capex optionality, not explosive growth. On Aug 12, listen for colour on disruption cost, capex momentum, and full-year guidance. The stock's current 8% discount to ATH suggests the market is waiting for reassurance before pushing higher.
Indo Count Q1 FY27: consolidated PAT +67% YoY to ₹63 Cr as margins expand toward guidance
PAT +67.29% YoY · revenue +25.9% · margins expanding · beat vs street
₹1,206.96 Cr
+25.9% YoY
₹63.22 Cr
+67.29% YoY
5.17%
+1.3pp YoY
₹3.19
Indo Count Industries' consolidated Q1 FY27 (quarter ended June 30, 2026) revenue came in at ₹1,206.96 Cr, up 25.9% YoY from ₹958.71 Cr and 14.1% QoQ from ₹1,057.68 Cr. Consolidated PAT was ₹63.22 Cr, up 67.3% YoY (₹37.79 Cr reported / ~62% on the ₹39.02 Cr restated base) and up 161% QoQ off a weak ₹24.20 Cr Q4 FY26 base — the QoQ jump is largely a base effect against a soft prior quarter rather than a fresh sequential acceleration, so the YoY read is the one to anchor on. Standalone told a similar story: revenue ₹819.44 Cr and PAT ₹66.78 Cr (EPS ₹3.37), actually ahead of the consolidated PAT of ₹63.22 Cr (EPS ₹3.19) because overseas subsidiaries collectively posted a small net loss (~₹3.39 Cr) this quarter per the auditor's review report — standalone and consolidated tell the same directional story, just with that overseas drag on the consol number.
Q1 FY-2027 vs prior quarters
Margins expanded on both counts: consolidated NPM rose to ~5.2% from ~3.9% a year ago, and EBITDA margin (OPM) to ~13.3% from ~11.5-12.5%. That expansion lines up with what management flagged on the last concall (Feb 2026) — a gradual march toward its 15-16% EBITDA target as tariff-related pressure eases and ~150-200bps of new-business incubation costs get eliminated starting this exact quarter, Q1 FY27. The margin move is roughly in that range, so this quarter's print looks like management delivering on that specific near-term promise, even though the 15-16% steady-state target itself remains some distance away.
The stock went into the print at ₹427.05, up 5.9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
Management reaffirms its long-term vision to double revenue by FY28, driven by the normalization of its core business and the scaling of new segments, which are expected to contribute approximately $275 million. They anticipate a gradual margin recovery towards their 15-16% EBITDA goal as tariff-related pressures ease
— This quarter: met
No formal brokerage consensus for the quarter turned up in search; the one projection found (Univest/Uniresearch, a trailing-growth model, not a brokerage note) had pegged revenue near ₹977 Cr (+2% YoY) and PAT near ₹20 Cr (-50% YoY) — the actual print beat that bar comfortably on both lines, though given the source isn't a real street consensus this should be read as a beat against a weak bar rather than a confirmed Street beat. Management gives no explicit quantified guidance for this specific quarter beyond the margin-recovery and incubation-cost commentary noted above; the longer-term FY28 revenue-doubling plan (new segments contributing ~$275 million) isn't independently verifiable this quarter since the company still reports a single textile segment with no sub-segment breakout. Corporate developments this quarter were largely administrative — BRSR filing, 37th AGM notice — except for the Bhilad (Gujarat) facility flooding since July 23, 2026, which management has flagged as a non-adjusting event with an insurance claim assessment in progress and no P&L effect recorded yet. Separately, the board is still seeking shareholder approval for ₹2.96 Cr of FY26 managerial remuneration paid above Schedule V limits.
W1
OPM trajectory toward management's 15-16% EBITDA-margin target — Q1 FY27 OPM ~13.3%, up from ~11.5-12.5% a year ago; watch for further gains in Q2 FY27 as incubation costs fully roll off
W2
Bhilad facility flood impact — insurance claim assessment in progress since July 23, 2026; watch Q2 FY27 for any recognized cost/volume drag or claim recovery
W3
New-segment revenue contribution toward the ~$275 million FY28 target — no segment-level disclosure this quarter (single reportable textile segment); watch for any future breakout
Clean digital filing, both statements tie out exactly (totalIncome and PAT=PBT-tax match to the rupee). Q1 FY26 comparative was later restated (PPA finalisation for two US acquisitions): reported PAT ₹37.79 Cr vs restated ₹39.02 Cr — YoY here uses the originally reported figure (matches our DB record); on restated base PAT YoY is ~62% instead of ~67%. Consol PAT (₹63.22 Cr) is below standalone PAT (₹66.78 Cr) because overseas subsidiaries posted a combined ~₹3.39 Cr net loss this quarter (per auditor review report). Bhilad flood (from 23-Jul-26) is a non-adjusting post-period event with no P&L impact yet. No exceptional/one-off P&L line this quarter, so no separate adjusted-PAT figure is needed.